Influence of SII and NLR on the survival time in patients with malignant obstructive jaundice treated with PTCD implantation of biliary mental stents

Abstract

Abstract: Objective To analyze the influence of inflammatory factors in patients with malignant obstructive jaundice (MOJ) implanted with biliary mental stents by percutaneous transhepatic cholangial drainage (PTCD). Methods Fourteen patients with MOJ treated with implantation of biliary mental stents by PTCD were enrolled. Levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil) and albumin were compared before and after implantation (at week 1, month 1 and 4). Preoperative clinical data were collected to calculate the inflammation indexes, including systemic immune-inflammation index (SII, neutrophil × platelets / lymphocyte), platelets-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio. Overall survival (OS) was estimated by the Kaplan-Meier method and Cox regression analysis. Results Levels of ALT, AST and TBil were significantly decreased after implantation operation, while albumin level was increased at month 4 after operation. During a median follow-up time of 10 months, 7 (50%) patients died. Additionally, SII and NLR were found to be associated with OS. Conclusion PTCD implantation of biliary mental stents is clinically feasible for patients with MOJ, and increased levels of SII and NLR are associated with poor OS after operation.

Key words: Malignant obstructive jaundice, Overall survival, Percutaneous transhepatic cholangial drainage, Systemic immune-inflammation index, Neutrophil-to-lymphocyte ratio

YUAN Xiao-ling, Bai Yu-pan, YIN Dong-lin, HONG Shen-zhen, Bao Yu-jie, ZHOU Yuan-yuan, YAN Lei, KANG Yao-yue, FAN Shan, CAO Jun-ying, XU Jie. Influence of SII and NLR on the survival time in patients with malignant obstructive jaundice treated with PTCD implantation of biliary mental stents[J]. Chinese Hepatolgy, 2018, 23(6): 492-495.

References

[1] Wang L, Yu WF. Obstructive jaundice and perioperative management. Acta anaesthesiologica Taiwanica, 2014, 52: 22-29.
[2] Tan DW, Fu Y, Su Q, et al. Prognostic Significance of Neutrophil to Lymphocyte Ratio in Oncologic Outcomes of Cholangiocarcinoma: A Meta-analysis. Sci Rep, 2016, 6: 33789.
[3] Guthrie GJ, Roxburgh CS, Farhan-Alanie OM, et al. Comparison of the prognostic value of longitudinal measurements of systemic inflammation in patients undergoing curative resection of colorectal cancer. Brit J Cancer, 2013, 109: 24-28.
[4] Coussens LM, Werb Z. Inflammation and cancer. Nature, 2002, 420: 860-867.
[5] Jin H, Pang Q, Liu H, et al. Prognostic value of inflammation-based markers in patients with recurrent malignant obstructive jaundice treated by reimplantation of biliary met al stents: A retrospective observational study. Medicine, 2017, 96: e5895.
[6] Yao D, Kunam VK, Li X. A review of the clinical diagnosis and therapy of cholangiocarcinoma. J Int Med Res, 2014, 42: 3-16.
[7] Choi JM, Kim JH, Kim SS, et al. A comparative study on the efficacy of covered met al stent and plastic stent in unresectable malignant biliary obstruction. Clin Endoscopy, 2012, 45: 78-83.
[8] Maluf-Filho F, Retes FA, Neves CZ, et al. Transduodenal endosonography-guided biliary drainage and duodenal stenting for palliation of malignant obstructive jaundice and duodenal obstruction. JOP Pancreas, 2012, 13: 210-214.
[9] Pan H, Liang Z, Yin TS, et al. Hepato-biliary-enteric stent drainage as palliative treatment for proximal malignant obstructive jaundice. Med Oncol, 2014, 31: 853.
[10] Soares KC, Kamel I, Cosgrove DP, et al. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobil Surg Nutr, 2014, 3: 18-34.
[11] Ha H, Nam AR, Bang JH, et al. Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. Oncotarget, 2016, 7: 76604-76612.
[12] Lolli C, Caffo O, Scarpi E, et al. Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. Frontiers in Pharmacology, 2016, 7: 376.
[13] Yang HB, Xing M, Ma LN, et al. Prognostic significance of neutrophil-lymphocyteratio/platelet-lymphocyteratioin lung cancers: a meta-analysis. Oncotarget, 2016, 7: 76769-76778.
[14] Xu X, Chen W, Zhang L, et al. Prognostic significance of neutrophil to lymphocyte ratio in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. Chin MedJ, 2014, 127: 4204-4209.
[15] Carr BI, Cavallini A, D'Alessandro R, et al. Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro. BMC Cancer, 2014, 14: 43.
[16] Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semi Thromb Hemosta, 2004, 30: 95-108.
[17] Buergy D, Wenz F, Groden C, et al. Tumor-platelet interaction in solid tumors. Int J Cancer J Int Cancer, 2012, 130: 2747-2760.
[18] Iwase R, Shiba H, Haruki K, et al. Post-operative lymphocyte count may predict the outcome of radical resection for gallbladder carcinoma. Anticancer Res, 2013, 33: 3439-3444.
[19] Fidler IJ, Schroit AJ. Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochimica et biophysica acta, 1988, 948: 151-173.
[20] Ren QQ, Fu SJ, Zhao Q, et al. Prognostic value of preoperative peripheral monocyte count in patients with hepatocellular carcinoma after liver transplantation. Tumour biol, 2016, 37: 8973-8978.
[21] Sasaki A, Iwashita Y, Shibata K, et al. Prognostic value of preoperative peripheral blood monocyte count in patients with hepatocellular carcinoma. Surgery, 2006, 139: 755-764.